Drug
Sofosbuvir clinical trials
Also written Sovaldi®, GS-7977, PSI-7977 and SOF.
- studies test it
- 175
- open now
- 2
- in phase 3
- 62
- first study started
- 2010
Keep track of what changes. Save the Sofosbuvir studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
175 studies that test it; most in 2015 (36)
| Year | Studies |
|---|---|
| 2010 | 3 |
| 2011 | 5 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 24 |
| 2015 | 36 |
| 2016 | 25 |
| 2017 | 18 |
| 2018 | 11 |
| 2019 | 11 |
| 2020 | 11 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 67
- Phase 3
- 62
- Phase 4
- 38
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 87 · Other 88
Gilead Sciences (51) · Bristol-Myers Squibb (8) · Humanity and Health Research Centre (6) · Tehran University of Medical Sciences (5) · Kirby Institute (5) · Assiut University (4) · Genuine Research Center, Egypt (4) · ANRS, Emerging Infectious Diseases (3)
Often tested with
Tested in the same studies.
Velpatasvir (48) · Ribavirin (42) · Daclatasvir (28) · Ledipasvir (16) · Simeprevir (14) · Ledipasvir, sofosbuvir drug combination (11) · Voxilaprevir (9) · Ritonavir (5)
Studies
Open first, then newest update. How each study uses Sofosbuvir is read from its arms, and is right about nine times in ten.
Testing it · 175
- Hepatitis C Treatment in Idaho County JailsNot yet recruitingNot applicableEastern Idaho Public HealthNCT06533319Written as sofosbuvir/velpatasvir
- Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected ChildrenRecruitingPhase 3Ain Shams UniversityNCT05854511Written as Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets
- Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During PregnancyActive, not recruitingPhase 4Catherine Anne ChappellNCT05140941Written as Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
- Expanding the Pool in Orthotopic Heart TransplantationCompletedPhase 2Mary E. Keebler, MDNCT03222531Written as sofosbuvir/velpatasvir
- Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With SofosbuvirCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02647632Written as Sofosbuvir
- Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject DrugsTerminatedNot applicableKirby InstituteNCT03981211Written as Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
- The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant RecipientsCompletedPhase 2Fernanda P Silveira, MD, MSNCT03819322Written as sofosbuvir/velpatasvir
- Study of DAA Treatment for Children and Adolescents With Active HCV Infection in CambodiaActive, not recruitingNot applicableANRS, Emerging Infectious DiseasesNCT05992077Written as Sofosbuvir/Daclatasvir
- The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant RecipientsActive, not recruitingPhase 2Amit D Tevar, MDNCT03809533Written as sofosbuvir/velpatasvir
- Four Different Experimental Drug Regimens to Standard of Care for the Treatment of Symptomatic Outpatients With COVID-19CompletedPhase 2Shin Poong Pharmaceutical Co. Ltd.NCT04532931Written as Sofosbuvir/daclatasvir
- 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedPhase 2/3Muhammad Radzi Abu HassanNCT04885855Written as Sofosbuvir 400 MG
- An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver DiseaseCompletedPhase 2Janssen Research & Development, LLCNCT02262728Written as Sofosbuvir
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedPhase 4M.D. Anderson Cancer CenterNCT05717400Written as Sofosbuvir
- Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)Status unknownPhase 4Macfarlane Burnet Institute for Medical Research and Public Health LtdNCT05016609Written as Sofosbuvir/Velpatasvir (Gilead)
- DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)CompletedPhase 4ANRS, Emerging Infectious DiseasesNCT03537196Written as Sofosbuvir 400 mg and Daclatasvir 60 mg
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as Sofosbuvir
- Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C InfectionCompletedPhase 4Elizabeth Krans, MDNCT03057847Written as Sofosbuvir/Velpatasvir
- Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) CirrhoticsCompletedPhase 3Tehran University of Medical SciencesNCT02596880Written as Sofosbuvir
- HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled TrialCompletedPhase 4Alexandria UniversityNCT04653818Written as Velpatasvir/Sofosbuvir
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedPhase 2Fondazione Italiana Linfomi - ETSNCT02836925Written as Ledipasvir+Sofosbuvir
See all 175 studies that test Sofosbuvir →
Given in every arm · 36 — Sofosbuvir is usual care beside what is tested
- Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and TanzaniaRecruitingEarly Phase 1Médecins du MondeNCT06159504Written as sofosbuvir/velpatasvir (SOF/VEL)
- Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirRecruitingPhase 4Kirby InstituteNCT03855917Written as Sofosbuvir 400mg [Sovaldi]
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedPhase 3National Hepatology & Tropical Medicine Research InstituteNCT02771405Written as Sofosbuvir
- Transplanting Hepatitis C Positive OrgansStatus unknownPhase 4Brigham and Women's HospitalNCT03086044Written as Sofosbuvir/velpatasvir
- Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral DrugsCompletedPhase 1ViriomNCT03706898Written as Sofosbuvir
- A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV StudyCompletedPhase 2University of DundeeNCT03236506Written as Sofosbuvir 400 MG
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 2AbbVieNCT02292719Written as Sofosbuvir
- Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]CompletedPhase 2/3Johns Hopkins Bloomberg School of Public HealthNCT03480932Written as Sofosbuvir
- Directly Observed Therapy for HCV in Chennai, IndiaCompletedPhase 2Johns Hopkins Bloomberg School of Public HealthNCT02541409Written as Sofosbuvir
- Open Label Study of the Efficacy and Safety of MBL-HCV1 in Combination With Oral Direct-Acting Antivirals in Patients Undergoing Liver Transplantation for Hepatitis CTerminatedPhase 2MassBiologicsNCT01532908Written as Sofosbuvir (Part 2)
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 1Gilead SciencesNCT02185794Written as SOF/VEL
- The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected SubjectsCompletedPhase 1/2Sunshine Lake Pharma Co., Ltd.NCT04202952Written as Sofosbuvir Tablet
- Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionCompletedPhase 2Gilead SciencesNCT02378935Written as SOF/VEL
- Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)CompletedPhase 2Merck Sharp & Dohme LLCNCT02601573Written as Sofosbuvir
- Comparative Study of Two Regiemns in Management of Sofosbuvir/Daclatasvir FailureCompletedNot applicableAssiut UniversityNCT03549832Written as Sofosbuvir
- Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated CirrhosisCompletedPhase 3Gilead SciencesNCT02996682Written as SOF/VEL
- Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenCompletedPhase 2Gilead SciencesNCT02536313Written as SOF/VEL/VOX
- Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and CirrhosisCompletedPhase 2Gilead SciencesNCT02781558Written as SOF/VEL
- Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B CirrhosisCompletedPhase 3Gilead SciencesNCT02201901Written as SOF/VEL
- Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV InfectionCompletedPhase 2Gilead SciencesNCT01909804Written as SOF
Showing 20 of 36.
As the comparator · 6 — what is tested is compared with Sofosbuvir
- A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 InfectionCompletedPhase 3AbbVieNCT02640157Written as Sofosbuvir
- A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus InfectionCompletedPhase 3AbbVieNCT02723084Written as sofosbuvir (SOF)
- Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19)Status unknownPhase 3Mansoura UniversityNCT04535869Written as Sofosbuvir 400 MG plus Daclatasvir 200mg
- Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole TabletWithdrawnPhase 4Radboud University Medical CenterNCT03389061Written as sofosbuvir/velpatasvir tablet
- A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 3Egyptian Liver HospitalNCT03186313Written as Sofosbuvir + Daclatasvir + Ribavirin
- Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV InfectionCompletedPhase 2/3Egyptian Liver HospitalNCT02483156Written as Sofosbuvir tablet (SOF) 400 mg - once daily
Codes
What other systems call Sofosbuvir · ClinicalTrials.gg INT006597
- MeSH (NLM) D000069474SofosbuvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) WJ6CA3ZU8BSOFOSBUVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1484911Confirmed FDA, Wikidata
- Wikidata Q2502747sofosbuvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C101263SofosbuvirOne source FDA
- DrugBank DB08934One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069474 | Sofosbuvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | WJ6CA3ZU8B | SOFOSBUVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1484911 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2502747 | sofosbuvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C101263 | Sofosbuvir | One source FDA |
| DrugBank | DB08934 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.